Maxim Group analyst Jason McCarthy has maintained their bullish stance on APRE stock, giving a Buy rating on January 5.
Jason McCarthy has given his Buy rating due to a combination of promising clinical results and strategic advantages within Aprea Therapeutics’ drug development program. The significant rise in Aprea’s stock value, approximately 70% since early November, coincides with encouraging data from its leading synthetic lethality program, ATRN-119. This program, focused on an ATR inhibitor, is gaining traction partly due to the overall recovery of the biotech market. Aprea’s continuous dosing strategy for ATRN-119, which differs from competitors’ intermittent dosing due to side effects, is showing a positive safety profile and early signals of durability in patients, which further underpins McCarthy’s positive outlook on the stock.
Moreover, the updated data from the phase 1/2a study of ATRN-119 in solid tumors with DNA-Damage Response mutations has revealed stable disease in patients, one of whom has maintained this state for 118 days. This positive outcome is seen as a validation of the continuous dosing approach, which aims to achieve a stronger synthetic lethal phenotype and, consequently, better therapeutic effects. McCarthy’s assessment likely factors in the comparative advantages of Aprea’s ATRN-119 over other ATR inhibitors, particularly in the context of side effect profiles and therapy effectiveness, bolstering his Buy recommendation for APRE stock.
In another report released on January 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
APRE’s price has also changed dramatically for the past six months – from $2.888 to $5.960, which is a 106.37% increase.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Aprea Therapeutics (APRE) Company Description:
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Read More on APRE:
